HELIOS Kliniken GmbH

The research at HELIOS Kliniken GmbH focuses on early-stage HER2-positive, HR-positive, PIK3CA mutant breast cancer, evaluating whether adding a novel PI3K inhibitor to standard endocrine therapy, pertuzumab, and trastuzumab can increase pathological complete response rates.

• Targeted combination therapy with HER2 and PI3K blockade
• Neoadjuvant endocrine treatment optimization
• Assessment of pathological complete response as a surrogate endpoint

The study aims to improve cure rates for patients by testing a new therapeutic strategy that could become a future standard of care.

In the dermatology unit, investigators are assessing the efficacy of amlitelimab, a subcutaneous biologic, for individuals aged 12 and older with moderate‑to‑severe atopic dermatitis who have not responded adequately to prior biologic or oral JAK inhibitor therapies.

• Biologic treatment options for refractory atopic dermatitis
• Subcutaneous delivery combined with topical corticosteroids
• Safety and efficacy in a pediatric‑adolescent population

This trial seeks to expand therapeutic choices for patients struggling with persistent eczema, offering a potentially effective and convenient new option.